Home Ingredients Lipase
Gut Health

Lipase

Lipase / triacylglycerol lipase (EC 3.1.1.3)
Evidence Level
Strong
2 Clinical Trials
4 Documented Benefits
4/5 Evidence Score

Lipase is the enzyme responsible for digesting dietary fats — hydrolyzing triglycerides into free fatty acids and monoglycerides that the small intestine can absorb. Endogenous lipases include lingual lipase, gastric lipase, and pancreatic lipase (the predominant fat-digesting enzyme in healthy individuals). Supplemental lipase is typically derived from microbial sources (Aspergillus, Rhizopus, Candida rugosa) or porcine pancreas. Most clinically important for individuals with reduced fat digestion capacity: pancreatic insufficiency, post-cholecystectomy patients, those on weight-loss medications affecting fat absorption (orlistat), or individuals consuming very high-fat ketogenic/keto diets.

Studied Dose OTC supplements: 1,000–10,000 USP lipase units per meal; Prescription PERT for pancreatic insufficiency: 10,000–80,000 USP lipase units per main meal
Active Compound Lipase enzyme measured in FCC FIP units, FCCC, or USP lipase units

Benefits

Improved fat digestion and reduced steatorrhea

Lipase supplementation directly addresses fat malabsorption — symptoms include greasy/oily stools, stool floating, light-colored stools, weight loss, and fat-soluble vitamin deficiencies (A, D, E, K). In documented pancreatic insufficiency, supplemental lipase is the cornerstone of treatment. Even subclinical lipase insufficiency (aging, alcohol use, post-cholecystectomy patients) can benefit from supplementation when consuming high-fat meals.

Supported by Trial 1, Trial 2

Reduced post-meal fullness and bloating with fatty meals

A double-blind RCT showed lipase-containing pancreatic enzyme supplementation reduced bloating (-60%), gas, and fullness following high-fat meals in healthy adults. Particularly relevant for individuals on high-fat ketogenic diets, those eating large portions of fried foods, dairy, or fatty proteins, and patients post-cholecystectomy with reduced bile flow capacity.

Supported by Trial 1

Fat-soluble vitamin absorption support

Lipase activity is required for absorption of fat-soluble vitamins (A, D, E, K), carotenoids, and essential fatty acids (EPA, DHA from fish oil). In conditions reducing endogenous lipase, supplementation prevents subclinical deficiencies. Particularly relevant for vegetarians/vegans relying on plant carotenoid conversion to vitamin A, and for omega-3 supplement users seeking maximum absorption.

Supported by Trial 2

Adjunct in cystic fibrosis and chronic pancreatitis

Pancreatic enzyme replacement therapy (PERT, including lipase) is the cornerstone of treatment for cystic fibrosis-related and chronic pancreatitis-related pancreatic insufficiency. Without lipase replacement, these patients develop progressive malnutrition, weight loss, fat-soluble vitamin deficiencies, and increased mortality. Decades of clinical evidence support routine lipase replacement in these populations.

Supported by Trial 2, Trial 1

Mechanism of action

1

Triglyceride hydrolysis at the sn-1 and sn-3 positions

Pancreatic lipase preferentially cleaves the ester bonds at sn-1 and sn-3 positions of triglycerides, producing free fatty acids and 2-monoglycerides (which are then absorbed by enterocytes). Microbial lipases (Aspergillus, Rhizopus) have broader specificity and can hydrolyze all three positions, providing more complete triglyceride breakdown.

2

Bile salt and colipase requirements

Pancreatic lipase requires emulsification of dietary fat by bile salts and activation by colipase (a small pancreatic protein cofactor). In bile flow disorders (post-cholecystectomy, cholestasis), even adequate lipase doses may underperform because fat emulsification is impaired. Microbial lipases are less bile-dependent and may work better in these settings.

3

Acid sensitivity and enteric coating

Pancreatic lipase is acid-sensitive (irreversibly inactivated below pH 4) — explaining why prescription PERT products use enteric coating to bypass gastric acid. Microbial lipases (Aspergillus, Rhizopus) are far more acid-stable (active at pH 2-7), making them preferred for OTC supplements that don't have enteric coating.

Clinical trials

1
Pancreatic Lipase for Functional Dyspepsia — Crossover RCT
PubMed

Randomized, double-blind, placebo-controlled crossover trial. Subjects ate high-fat meal with placebo or pancrelipase (Creon® or similar pharmaceutical). Outcomes: postprandial bloating, gas, fullness, fecal fat. (Suarez et al. 1999, Gastroenterology)

Healthy adults consuming high-fat meal.

Bloating reduced ~60%, gas ~49%, fullness ~43%. Fecal fat excretion reduced. Validated lipase efficacy beyond clinical pancreatic insufficiency.

2
Microbial Lipase vs Pancrelipase — Crossover RCT

Randomized, double-blind crossover trial comparing microbial lipase (Rhizopus oryzae-derived) to porcine pancrelipase in patients with pancreatic insufficiency. (2017)

Pancreatic insufficiency patients.

Microbial lipase showed similar efficacy to porcine pancrelipase in some patients; some required higher doses. Pharmaceutical pancrelipase remains gold standard for clinical pancreatic insufficiency (CF, chronic pancreatitis).

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated
GI upset, nausea, diarrhea in some users
Hyperuricemia (porcine source contains purines)
Allergic reactions to enzyme source (porcine, fungal) in sensitized individuals
Excessive doses can cause loose, oily stools (over-digestion of fats)

Important Drug interactions

Orlistat (Xenical, Alli) — antagonistic; lipase will overcome orlistat's intended fat-blocking action
Acarbose, miglitol — antagonistic; pancrelipase will overcome alpha-glucosidase inhibition
Iron supplements — may reduce iron absorption; separate by 2 hours
Generally compatible with other medications

Featured in these supplement guides

Bloating→

More Gut Health Ingredients

Metabolic Health
Psyllium Husk (Plantago ovata)
Psyllium husk is the soluble fiber derived from the seed husks of Plantago ovata — the mos…
Gut Health
Pancrelipase / Pancreatin
Pancrelipase (also called pancreatin) is a standardized blend of three primary pancreatic…
Gut Health
Sunfiber® (Partially Hydrolyzed Guar Gum)
Sunfiber® is the original and most extensively clinically-studied partially hydrolyzed gua…
Immune Support
EpiCor® (Postbiotic Yeast Fermentate — Cargill)
EpiCor® is a postbiotic ingredient from Cargill — derived from the fermentation of Sacchar…

Frequently asked questions about Lipase

What is lipase?

Lipase is the digestive enzyme that breaks down dietary fats into absorbable fatty acids. The pancreas produces it, and supplemental lipase is included in digestive-enzyme blends to support fat digestion.

What is lipase used for?

Supplemental lipase helps people who feel they digest fatty meals poorly, easing the heaviness, bloating, or discomfort that can follow rich meals. It is essential (in prescription strength) for those with pancreatic insufficiency.

When should I take lipase?

Take it at the start of a meal, especially fat-containing meals, so it is present as food is digested. It is usually combined with amylase and protease in digestive blends.

Is lipase safe?

Supplemental lipase is generally well tolerated. Serious fat-malabsorption conditions need prescription enzymes and medical supervision, so do not self-treat them with general supplements.

What is the recommended dosage of Lipase?

The clinically studied dose is OTC supplements: 1,000–10,000 USP lipase units per meal; Prescription PERT for pancreatic insufficiency: 10,000–80,000 USP lipase units per main meal Always follow the product label and check with a healthcare provider for personal advice.

Is Lipase safe, and does it have side effects?

For most healthy adults, Lipase is well tolerated at studied doses. Reported effects can include: Generally well-tolerated GI upset, nausea, diarrhea in some users It may also interact with some medications. Lipase is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Lipase interact with any medications?

Possible interactions include: Orlistat (Xenical, Alli) — antagonistic; lipase will overcome orlistat's intended fat-blocking action Acarbose, miglitol — antagonistic; pancrelipase will overcome alpha-glucosidase inhibition If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Lipase?

NutraSmarts rates the evidence for Lipase as Strong (4 out of 5). It is backed by 2 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. de la Iglesia-Garcia D, Huang W, Szatmary P, Baston-Rey I, Gonzalez-Lopez J, Prada-Ramallal G, et al. Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis Gut. 2017;66(8):1354-1355. doi: 10.1136/gutjnl-2016-312529.PubMedUsed to support: Meta-analysis establishing that pancreatic enzyme replacement therapy (containing lipase) improves fat absorption (coefficient of fat absorption) in chronic pancreatitis; supports PERT for exocrine pancreatic insufficiency. Honest framing: evidence is for documented insufficiency, not general digestion.
  2. Whitcomb DC, Lehman GA, Vasileva G, Malecka-Panas E, Gubergrits N, Shen Y, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: a double-blind randomized trial Am J Gastroenterol. 2010;105(10):2276-86. doi: 10.1038/ajg.2010.201.PubMedUsed to support: Pivotal RCT showing lipase-containing pancrelipase improved fat absorption and steatorrhea in exocrine pancreatic insufficiency from chronic pancreatitis/pancreatic surgery; anchors the well-established PERT indication.
  3. Somaraju URR, Solis-Moya A Pancreatic enzyme replacement therapy for people with cystic fibrosis Cochrane Database Syst Rev. 2020;8(8):CD008227. doi: 10.1002/14651858.CD008227.pub4.PubMedUsed to support: Cochrane review of PERT (lipase) in cystic fibrosis-related pancreatic insufficiency; supports established clinical use for fat malabsorption. Honest framing: indication is pancreatic insufficiency, not OTC 'fat burning' or bloating.
  4. Lohr JM, Dominguez-Munoz E, Rosendahl J, Besselink M, Mayerle J, Lerch MM, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU) United European Gastroenterol J. 2017;5(2):153-199. doi: 10.1177/2050640616684695.PubMedUsed to support: Authoritative clinical guideline establishing enzyme (lipase) replacement as standard therapy for exocrine pancreatic insufficiency; used to frame PERT as well-established while OTC general-digestion use remains unproven.